Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nyxol with or without low-dose pilocarpine in presbyopia
NCT05646719Phase 3Completed
- Sponsor
- Opus Genetics
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of phentolamine in presbyopia (6 arms), sponsored by Opus Genetics. Primary endpoint: Percent of Subjects With >= 15 Letters of Improvement in Photopic Binocular DCNVA and With < 5 Letters of Loss in Photopic Binocular BCDVA at Day 8. Started Dec 2022; status: completed.
02
Drugs
phentolamine
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT05646719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646719.